ArticleArthritis research & therapy2010
Remission in psoriatic arthritis: is it possible and how can it be predicted?
Article in Arthritis research & therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03330769 (Ultrasound in PSoriatic Arthritis TREAtMent - UPSTREAM), which is not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ultrasound in PSoriatic Arthritis TREAtMent - UPSTREAM
Who cites it
32 citing papers in PubMed, 88 citations in OpenAlex.
- The development of a clinical prediction model for response to methotrexate, tofacitinib, and etanercept in patients with Psoriatic Arthritis.Arthritis research & therapy · 2025Trial
- Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1.Rheumatology (Oxford, England) · 2023Trial
- Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.Annals of the rheumatic diseases · 2022Trial
- Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.Arthritis care & research · 2017Trial
- Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world.BioMed research international · 2014Trial
- Randomized controlled trial of a nurse-led rheumatology clinic for monitoring biological therapy.Journal of advanced nursing · 2014Trial
- Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries.Rheumatology (Oxford, England) · 2024Article
- Therapeutic Effects of Apremilast on Enthesitis and Dactylitis in Real Clinical Setting: An Italian Multicenter Study.Journal of clinical medicine · 2023Article
- Article
- Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy.Rheumatology (Oxford, England) · 2021Review
- Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years.Scientific reports · 2021Article
- Long-term remission and biologic persistence rates: 12-year real-world data.Arthritis research & therapy · 2021Article
- Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.Frontiers in medicine · 2021Article
- Predicting functional disability in patients with spondyloarthritis using a CRP-based algorithm: A 3-year prospective study.Experimental and therapeutic medicine · 2021Article
- Is It Possible to Discontinue Tumor Necrosis Factor Antagonists after Psoriasis Remission?Annals of dermatology · 2019Review
- Dysregulated miR-125a promotes angiogenesis through enhanced glycolysis.EBioMedicine · 2019Article
- Article
- Observational
- Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis.Arthritis research & therapy · 2017Review
- Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis.RMD open · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSince remission is now possible in psoriatic arthritis (PsA) we wished to examine remission rates in PsA patients following anti tumour necrosis factor alpha (TNFalpha) therapy and to examine possible predictors of response.
methodsAnalysis of a prospective patient cohort attending a biologic clinic, between November 2004 and March 2008, was performed prior to commencing therapy and at regular intervals. Baseline clinical characteristics including demographics, previous disease-modifying antirheumatic drug (DMARD) response, tender and swollen joint counts, early morning stiffness, pain visual analogue score, patient global assessment, C reactive protein (CRP) and health assessment questionnaire (HAQ) were collected.
resultsA total of 473 patients (152 PsA; 321 rheumatoid arthritis (RA)) were analyzed. At 12 months remission, defined according to the disease activity score using 28 joint count and CRP (DAS28-CRP), was achieved in 58% of PsA patients compared to 44% of RA patients, significant improvement in outcome measures were noted in both groups (P<0.05). Analysis of a subgroup of PsA and RA patients matched for DAS28-CRP at baseline also showed higher numbers of PsA patients achieving remission. Linear regression analysis identified the HAQ at baseline as the best predictor of remission in PsA patients (P<0.001).
conclusionsDAS28 remission is possible in PsA patients at one year following anti-TNF therapy, at higher rates than in RA patients and is predicted by baseline HAQ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.